Melinda Gooderham

1. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
   2022/11/29 by Georgios Kokolakis, Richard B Warren, Richard B. Warren +16 · 9 citations
   Immunology and Microbiology · Medicine · Biochemistry, Genetics and Molecular Biology · #Psoriasis: Treatment and Pathogenesis #Spondyloarthritis Studies and Treatments #Inflammatory Bowel Disease
2. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
   2023/01/01 by April W. Armstrong, Melinda Gooderham, Richard B. Warren +13 · 1 citation